

CURRICULUM VITAE

CURRICULUM VITAE



Personal information

Name Francesca Spinella
Nationality Italian
Date of birth 08/07/1970
E-mail francesca.spinella@unicamillus.org

CURRENT EMPLOYMENT STATUS

Associate Professor of Applied Biology Departmental Faculty of Medicine Saint Camillus International University of Health and Medical Sciences, Via di Sant'Alessandro, 8 - 00131 Rome, Italy Tel: 39-06-400640

Medical Science Liaison
Eurofins GENOMA Group s.r.l. Via di Castel Giubileo, 11, 00138 Rome, Italy.
Molecular Genetics Laboratory
Via Di Castel Giubileo, 11, Roma

Work EXPERIENCE

From -to 3-1-2014 today
Name and address of employer Eurofins GENOMA Group s.r.l. Via di Castel Giubileo, 11, 00138 Rome, Italy.
Molecular Genetics Laboratory
Via Di Castel Giubileo, 11, Roma
Occupation Medical Science Liaisons

Chair of ESHRE PGT-Consortium
Member of ULTRAPLACAD External Advisory Board (EAB)

From-to 9-1-2001 31-12-2013
Name and address of employer Molecular Pathology Laboratory
Experimental Research Center of the Tumor National Regina Elena Institute in Rome (IFO)
Via delle Messi d'Oro 156, Roma

Occupation

Contract Researcher: AIRC Research Project Manager Study of the molecular mechanisms of endothelin receptors: analysis of the pathways underlying the development, proliferation and migration of tumor cells induced by endothelin receptor A and B ligands in vitro and in mouse models.

EDUCATION

1990-1995
Degree in Biological Science
University of Catania, Italy,
Faculty of Biological Science

1995-1999
PhD in Neurobiology
University of Catania, Italy

**SCIENTIFIC
QUALIFICATION**

In 2012 she obtained the National scientific qualification (art. 16 della legge 240/2010) to function as associate professor in **05/E2 - BIOLOGIA MOLECOLARE**

In 2012 she obtained the National scientific qualification (art. 16 della legge 240/2010) to function as associate professor in **05/E1- BIOCHIMICA GENERALE E BIOCHIMICA CLINICA**

[Abilitazione Scientifica Nazionale \(cineca.it\)](http://cineca.it)

In 2018 she obtained the National scientific qualification to function as full professor in - **05/F1- BIOLOGIA APPLICATA**

**ADDITIONAL
INFORMATION**

Participation in national and international conferences as a speaker:

- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting 7-10 /7/2024
- International congress of human reproduction-BRNO
- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting 10-12/7/2023
- ALMER Congress, Cartagena Evolución de las indicaciones para PGT10-12/5/2023
- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting 2022
- 2021 European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting virtual meeting. 26-1 July 2021.
- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting Virtual meeting: 5-8 July 2020
- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. Vienna 2019, 23-26 June 2019. Invited speaker "Impact of chromosomal mosaicism in IVF outcomes".
- Lesson for the teaching of human genetics (master's degree in genetics and molecular biology), at the Sapienza University of Rome. Title: Clinical applications of Next generation sequencing " Rome, May 14th 2019
- European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting. "New evidence on mosaic developmental potential: two hundred mosaic embryos transferred prospectively in a single clinic " Vienna 2019, 23-26 June 2019. Selected oral presentation
- Seminar in Applied Human Genetics, Sapienza University Rome part of the PhD program in Genetics and Molecular Biology. Title: "Clinical application of next generation sequencing" Rome, 18-January 2018.
- Preimplantation Genetic Diagnosis International Society (PGDIS), Ginevra 15-18 April 2018
- 4° European Fertility Meeting: Strategies to improve IVF success rate Congresso Nazionale SIRU. Rome, 1-2 December, 2018
- SIRU Annual Congress "Costruiamo la medicina e la biologia della riproduzione umanizzata". Rome, 14-16 December 2017
- Preimplantation Genetic Diagnosis International Society (PGDIS), Valencia 26-29 March 2017
- Preimplantation Genetic Diagnosis International Society (PGDIS), Bologna 8-11 May 2016
- Preimplantation Genetic Diagnosis International Society (PGDIS), Chicago 9-13 May 2015
- American Society Reproductive Medicine (ASRM) Annual Meeting-Honolulu, Hawaii-18-22 October 2014
- 13th International Conference on Endothelin, Tokyo, Japan, 11 September 2013 (Keynote lecture)
- 12th International Conference on Endothelin, Cambridge, 11 September 2011

<p>Professional Experience</p> <p>3/01/2014 to 31/12/2022</p> <p>12/3/2019 to 12/12/2021</p> <p>3/1/2022 to 31/12/2023</p> <p>Since 2022</p>	<ul style="list-style-type: none"> • Centro Ricerca Sperimentale; Istituto Regina Elena, Roma 3-Marzo 2009 • Seminario presso l’Istituto Dermatologico Italiano, Roma 10 Febbraio 2009 • Workshop SIICA, Angiogenesi: basi molecolari ed implicazioni terapeutiche II, Siena 21-23 Maggio 2008 • Congresso Nazionale della Società Italiana di Cancerologia, Bergamo, 26-Novembre, 2007 • Centro Ricerca Sperimentale; Istituto Regina Elena Roma 14 Novembre 2007 • 10th International Conference on Endothelin, Bergamo, 25 Settembre 2007 • Pezcoller Foundation Symposium. Pordenone, 10 Settembre 2007 • 9th International Conference on Endothelin. Park City, Utah, 11 Settembre 2005 • Meeting “Meccanismi di trasduzione del segnale in adesione e differenziamento cellulare”, Roma 19 Marzo 2004 <p>R&D director. Eurofins Genoma Group. Development and validation of new techniques for Preimplantation Genetic Testing and Non Invasive Prenatal Testing (NIPT). Implementation of new CHIP for detection of somatic mutation.</p> <p>COVID Lab Manager, Eurofins Genoma Group</p> <p>International Scientific and Commercial Manager, Eurofins Genoma Group</p> <p>Revisor for International Journals</p> <p>Extensive experience as a reviewer for renowned international journals, including but not limited to Human Reproduction, Fertility and Sterility, PloONE, and RBMO.</p> <p>Research Project Reviewer for the Italian Association for Cancer Research (AIRC). Actively involved in reviewing research projects for the AIRC, contributing to the advancement of cancer research initiatives.</p> <p>Event Organization within the European Society of Human Reproduction and Embryology (ESHRE). Spearheading seminars and courses as part of the European Society of Human Reproduction and Embryology (ESHRE), fostering collaboration and knowledge exchange within the field of embryology peer-review process for the selection of research proposals</p>
---	--

Member of ULTRAPLACAD External Advisory Board (EAB)

Monitoring the progress of the HORIZON 2020 project focused on developing a plasmonic-based analytical platform with integrated nanostructures. This device is designed to concurrently analyze mutated **DNAs, microRNAs, and** tumor autoantibodies (a-TAAs). <https://ultraplacad.eu/project-team/>


Membership

Chair of the PGT Consortium ESHRE

Patent “Metodo per la diagnosi in vitro di un cancro di testa e collo e relativo kit”. The national patent was filed in 2019 and the international one in 2021 (excluding the USA). Domanda di Brevetto per Invenzione No. 102020000017896 depositata in Italia il 23/07/2020

Prize and Grant

- Pezcoller Foundation, Pezcoller Foundation Symposium. Pordenone, September 10-15, 2007
- The Fourth International Conference on "Tumor microenvironment: progression, therapy and prevention" Florence, March 6-10, 2007
- Travel Award Ninth International Conference on Endothelin. Park City, Utah , September 11-14 , 2005
- **Funding for research projects**
- “Progetto Giovani Ricercatori 2000-MURST “
- Principal Investigator “My First Grant” finanziato dall’AIRC 2010/2012.
- “POR FESR Lazio 2014-2020 CONTRIBUTI PER IL SOSTEGNO DEI PROCESSI DI INTERNAZIONALIZZAZIONE DELLE PMI DEL LAZIO Lazio Innova “
- “POR FESR 2014-2020”



Publications

- 1) Ciccarelli R., Suredda F., Casabona G., Di Iorio P., Caruso A., Spinella F., Condorelli D.F., Nicoletti F, and Caciagli F. *Opposite influence of metabotropic glutamate receptor subtypes mGlu3 and 5 on astrocyte proliferation in culture.* **Glia** (1997) 4:390-398. **I.F. 4.3**
- 2) Condorelli D.F., Dell'Albani P., Corsaro M., Giuffrida R., Caruso A., Trovato Salinaro A., Spinella F., Nicoletti F., Albanese V., and Giuffrida Stella A. M. *Metabotropic glutamate receptor expression in cultured rat astrocytes and human gliomas.* **Neurochem Res** (1997) 9:1127-1133. **I.F. 2.2**
- 3) Condorelli D.F., Parenti R., Spinella F., Trovato Salinaro A., Belluardo N., Cardile V. and Cicirata F. *Cloning of a new gap junction gene (Cx36) highly expressed in mammalian brain neurons.* **Eur J Neurosci** (1998) 10: 1202-1208. **I.F. 4**
- 4) Condorelli D.F., Trovato Salinaro A., Spinella F., Valvo S., Saponara R., and Giuffrida S. *Rapid touchdown PCR assay for the molecular diagnosis of spinocerebellar ataxia type 2.* **Int J Clin Lab Res** (1998) 28: 174-178. **I.F. 1.2**
- 5) Huang C.J., Spinella F., Nazarian R., Lee M.M., Dopp J.M. and de Vellis J. *Expression of Green Fluorescent Protein in Oligodendrocytes in a Time- and Level-Controllable Fashion with a Tetracycline-Regulated System.* **Mol Med** (1999) 2:129-137. **I.F.3.35**
- 6) Giuffrida S., Lanza S., Restivo D.A., Saponara R., Valvo S.C., Le Pira F., Salinaro A.T., Spinella F., Nicoletti A., and Condorelli D.F. *Clinical and molecular analysis of 11 Sicilian SCA2 families: influence of gender on age at onset.* **Eur J Neurol** (1999) 3: 301-307. **I.F. 4**
- 7) Cicirata F., Parenti R., Spinella F., Giglio S., Tuorto F., Zuffardi O., and Gulisano M. *Genomic organization and chromosomal localization of the mouse Connexin36 (mCx36) gene.* **Gene** (2000) 251:123-130 . **I.F. 2.7**
- 8) Gulisano M., Parenti R., Spinella F. and Cicirata F. *Cx36 is dynamically expressed during early development of mouse brain and nervous system.* **NeuroReport** (2000) 11: 3823-3828. **I.F. 2**
- 9) Rosanò L., Varmi M., Di Castro V., Spinella F., Natali P.G. and Bagnato A.. *Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.* **Cancer Res** (2001) 61: 8340-8346. **I.F. 8.6**
- 10) Del Bufalo D., Di Castro V., Biroccio A., Varmi M., Salani D., Rosanò L., Trisciuglio D., Spinella F. and Bagnato A. *Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for AKT activation.* **Mol Pharmacol** (2002) 61: 524-532. **I.F. 4.6**
- 11) Spinella F., Rosanò L, Di Castro V, Natali PG, Bagnato A. *Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells.* **J Biol Chem** (2002) 277: 27850-27855. **I.F. 5.85**
- 12) Rosanò L., Salani D., Di Castro V., Spinella F., Natali PG., and Bagnato A. *Endothelin-1 promotes proteolytic activity of ovarian carcinoma.* **Clin Sci** (2002) 102: 306S-309S. **I.F. 2.6**
- 13) Salani D., Rosanò L., Di Castro V., Spinella F., Venuti A., Padley R.J., Nicotra M.R., Natali PG., and Bagnato A. *ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian growth in vitro.* **Clin Sci** (2002) 102: 318S-21S. **I.F. 2.6**
- 14) Del Bufalo D., Di Castro V., Biroccio A., Salani D., Rosanò D., Spinella F., and Bagnato A. *Endothelin-1 acts as a survival factor in ovarian carcinoma cells.* **Clin Sci** (2002) 102: 302S-305S. **I.F. 2.6**
- 15) Dopp JM., Sarafian TA., Spinella F., Kahn MA., Shau H., de Vellis J. *Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells.* **Neurochem Res** (2002) 27:1535-1542. **I.F. 2.2**
- 16) Bagnato A., Spinella F. *Emerging role of endothelin-1 in tumor angiogenesis.* **Trends Endocr Metab** (2003) 1: 44-50. **I.F. 7.22**
- 17) Rosanò L., Spinella F., Salani D., Di Castro V., Venuti A., Nicotra M.R., Natali P.G., Bagnato A. *Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma.* **Cancer Res** (2003) 63: 2447-2453. **I.F. 8.6**
- 18) Rosanò L., Spinella F., Di Castro V., Ricci R., Nicotra M.R., Albini A., Natali P.G., Bagnato A. *Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo.* **Am J Pathol** (2003) 63:2447-2453. **I.F. 5.79**
- 19) Spinella F., Rosanò L., Di Castro V., Nicotra MR., Natali P.G., Bagnato A. *Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells.* **J Biol Chem** (2003) 278:41294-41301. **I.F. 5.85**
- 20) Bagnato A., Rosanò L., Spinella F., Di Castro V., Tecce R., Natali P.G. *Endothelin B receptor blockade inhibits*

- dynamics of cell interactions and communications in melanoma cell progression. Cancer Res* (2004) 64: 1436-1443. **I.F. 8.6**
- 21) Spinella F., Rosanò L., Di Castro V., Nicotra M.R., Natali P.G., Bagnato A. *Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin A receptor in human ovarian carcinoma cells. Clin Cancer Res* (2004) 10: 4670-4679. **I.F. 7.8**
 - 22) Spinella F., Rosanò L., Di Castro V., Natali P.G., Bagnato A. *Endothelin-1-induced prostaglandin E2-EP2,EP4-signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem* (2004) 279: 46700-46705. **I.F. 5.85**
 - 23) Rosanò L., Spinella F., Genovesi G., Di Castro V., Natali P.G. and Bagnato A, *Endothelin B receptor blockade inhibits molecular effectors of melanoma cell progression. J Cardiovasc Pharmacol* (2004) 44, S136-S139. **I.F. 1.13**
 - 24) Rosanò L., Spinella F., Di Castro V., Natali P.G., Bagnato A. *Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma: efficacy of the cytotoxic agents is markedly enhanced by coadministration with atrasentan. J Cardiovasc Pharmacol* (2004) 44, S132-S135. **I.F. 1.13**
 - 25) Spinella F., Rosanò L., Elia G., Di Castro V., Natali P.G., Bagnato A. *Endothelin-1 stimulates cyclooxygenase-2 expression in human ovarian carcinoma cells through multiple signaling pathways: evidence for involvement of the epidermal growth factor receptor. J Cardiovasc Pharmacol* (2004) 44, S140-S143. **I.F. 1.13**
 - 26) Bagnato A., Spinella F., Rosanò L. *Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer* (2005) 12:761-72. **I.F. 4.9**
 - 27) Rosanò L., Spinella F., Di Castro V., Nicotra M.R., Dedhar S., de Herreros AG., Natali P.G., Bagnato A. *Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res* (2005) 65:11649-57. **I.F. 8.6**
 - 28) Rosanò L., Spinella F., Di Castro V., Dedhar S., Nicotra M.R., Natali P.G., Bagnato A. *Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther* (2006) 5:833-42. **I.F. 5.1**
 - 29) Rosanò L., Di Castro V., Spinella F., Decandia S., Natali P.G., Bagnato A. *ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med* (2006) 231:1132-5. **I.F. 2.8**
 - 30) Rosanò L., Spinella F., Di Castro V., Decandia S., Nicotra M.R., Natali P.G., Bagnato A. *Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med* (2006)231:1128-31. **I.F. 2.8**
 - 31) Spinella F., Rosanò L., Decandia S., Di Castro V., Albini A., Elia G., Natali P.G., Bagnato A. *Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp Biol Med* (2006) 231:1123-7. **I.F. 2.8**
 - 32) Spinella F., Rosanò L., Decandia S., Di Castro V., Albini A., Nicotra M.R., Natali P.G., Bagnato A. *Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther* (2006) 5:1483-92. **I.F. 5.1**
 - 33) Spinella F., Rosanò L., Di Castro V., Decandia S., Nicotra M.R., Natali P.G., Bagnato A. *Endothelin-1 and -3 promote invasive behaviour via hypoxia-inducible factor-1a in human melanoma cells. Cancer Res.* (2007) 67 : 1725-1734. **I.F. 8.6**
 - 34) Rosanò L., Di Castro V., Spinella F., Nicotra M.R., Natali P.G. and Bagnato A. *ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther* (2007) 6: 2003-11. **I.F. 5.1**
 - 35) Rosanò L., Di Castro V., Spinella F., Tortora G., Nicotra M.R., Natali P.G. and Bagnato A. *Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res* (2007) 67:6351-9 **I.F. 8.6**
 - 36) Bagnato A., Spinella F., Rosanò L. *The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol.* (2008) 8:473-84 **I.F. 1.8**
 - 37) Rosanò L., Cianfrocca R., Masi S., Spinella F., Di Castro V., Biroccio A., Salvati E., Nicotra M.R., Natali P.G., and Bagnato A. *β -arrestin links endothelin A receptor to β -catenin signaling to induce ovarian cancer cell invasion and metastasis. PNAS* (2009) 106:2806-11 **I.F. 9.598**
 - 38) Spinella F., Emirena G., Di Castro V., Rosanò L., Nicotra M.R., Caruso A., Natali P.G., and Bagnato A. *Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res.* (2009) 69: 2669-76 **I.F.8.6**
 - 39) Rosanò L, Spinella F., Bagnato A. *The importance of endothelin axis in initiation, progression and therapy of*

ovarian cancer. **Am J Physiol Regul Integr Comp Physiol.** (2010). **I.F.3.3**

- 40) Spinella F, Rosanò L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, Bagnato A. *Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.* **PLoS One.** (2010) 5:e11241 **I.F.4.5**
- 41) Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A. *Combination therapy of zibotentan with cisplatin and paclitaxel is an effective regimen for epithelial ovarian cancer.* **Can J Physiol Pharmacol.** (2010) 88:676-81. **I.F.1.76**
- 42) Spinella F, Caprara V, Garrafa E, Di Castro V, Rosanò L, Natali PG, Bagnato A. *Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells.* **Can J Physiol Pharmacol.** (2010) 88:782-7. **I.F.1.76**
- 43) Cianfrocca R, Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A. *Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase.* **Can J Physiol Pharmacol.** (2010) 88 :796-801. **I.F.1.76**
- 44) Rosano L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A. *Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.* **Clin Cancer Res.** (2011) 17:2350-60. **I.F. 7.8**
- 45) Cianfrocca R, Tocci P, Spinella F, Di Castro V, Bagnato A, Rosanò L. *The endothelin A receptor and epidermal growth factor receptor signaling converge on β -catenin to promote ovarian cancer metastasis.* **Life Sci.** (2012) 91:550-6 **I.F. 2.5**
- 46) Garrafa E, Caprara V, Di Castro V, Rosanò L, Bagnato A, Spinella F. *Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells.* **Life Sci.** (2012) **I.F. 2.5**
- 47) Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A, La Sorda R, Spinella F, Bagnato A, Lattanzio R, D'Egidio M, Di Risio A, Stampolidis P, Piantelli M, Natoli C, Ullrich A, Iacobelli S. *LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.* **J Mol Med (Berl).** (2013) 91:83-94. **I.F. 5.3**
- 48) Spinella F, Caprara V, Di Castro V, Rosanò L, Cianfrocca R, Natali PG, Bagnato A. *Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.* **J Mol Med (Berl).** (2013) 91:395-405. **I.F. 5.3**
- 49) Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A. *β -arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β -catenin signaling.* **Oncogene.** (2013) Dec 3. **I.F. 6.9**
- 50) Rosanò L, Spinella F, Bagnato A. *Endothelin 1 in cancer: biological implications and therapeutic opportunities.* **Nat Rev Cancer.** (2013) 13:637-51. **I.F. 35**
- 51) Salvati E, Zizza P, Rizzo A, Iachettini S, Cingolani C, D'Angelo C, Porru M, Randazzo A, Pagano B, Novellino E, Pisanu ME, Stoppacciaro A, Spinella F, Bagnato A, Gilson E, Leonetti C, Biroccio A. Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. **Nucleic Acids Res.** (2014) 42:2945-57. **I.F. 8.2**
- 52) Spinella F, Caprara V, Cianfrocca R, Rosanò L, Di Castro V, Garrafa E, Natali PG, Bagnato A. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. **Carcinogenesis.** (2014) 35:840-8. **I.F. 5.6**
- 53) Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, Rosanò L. β -Arrestin 1 is required for endothelin-1-induced NF- κ B activation in ovarian cancer cells. **Life Sci.** (2014). doi: 10.1016/j.lfs.2014.01.078. **I.F. 2.6**
- 54) Traini S, Piccolo E, Tinari N, Rossi C, La Sorda R, Spinella F, Bagnato A, Lattanzio R, D'Egidio M, Di Risio A, Tomao F, Grassadonia A, Piantelli M, Natoli C, Iacobelli S. Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. **Mol Cancer Ther.** (2014) 13:916-25. **I.F. 5.6**
- 55) Caprara V, Scappa S, Garrafa E, Di Castro V, Rosanò L, Bagnato A, Spinella F. Endothelin-1 regulates hypoxia-inducible factor-1 α and -2 α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. **Life Sci.** (2014) pii: S0024-3205(14)00287-2. **I.F. 2.5**
- 56) Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A. Endothelin A receptor/ β -arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. **Cancer Res.** (2014);74:7453-64. **I.F.8.6**

- 57) Bono S, Biricik A, Spizzichino L, Nuccitelli A, Minasi MG, Greco E, Spinella F, Fiorentino F. Validation of a semiconductor next-generation sequencing (NGS)-based protocol for preimplantation genetic diagnosis of reciprocal translocations. **Prenat Diagn.** 35:938-44. 2015 **I.F. 2.5**
- 58) Fiorentino F, Bono S, Pizzuti F, Mariano M, Polverari A, Duca S, Sessa M, Baldi M, Diano L, Spinella F. The importance of determining the limit of detection of non-invasive prenatal testing methods. **Prenat Diagn.** 2016 36:304-11. **I.F. 2.5**
- 59) Fiorentino F, Bono S, Pizzuti F, Mariano M, Polverari A, Duca S, Sessa M, Baldi M, Diano L, Spinella F. Response to "The importance of determining the limit of detection of non-invasive prenatal testing methods". **Prenat Diagn.** 2016;36:898-9. **I.F. 2.5**
- 60) Minasi MG, Colasante A, Riccio T, Ruberti A, Casciani V, Scarselli F, Spinella F, Fiorentino F, Varricchio MT, Greco E. Correlation between aneuploidy, standard morphology evaluation and morphokinetic development in 1730 biopsied blastocysts: a consecutive case series study. **Hum Reprod.** 2016;31:2245-54. **I.F. 5.02**
- 61) Fiorentino F, Bono S, Pizzuti F, Mariano M, Polverari A, Duca S, Sessa M, Baldi M, Diano L, Spinella F. The importance of determining the limit of detection of non-invasive prenatal testing methods. **Prenat Diagn.** 2016;36:304-11. **I.F. 5.02**
- 62) Fiorentino F, Bono S, Pizzuti F, Duca S, Polverari A, Faieta M, Baldi M, Diano L, Spinella F. The clinical utility of genome-wide non invasive prenatal screening. **Prenat Diagn.** 2017;37:593-601. **I.F. 5.02**
- 63) Fiorentino F, Bono S, Pizzuti F, Duca S, Polverari A, Faieta M, Baldi M, Diano L, Spinella F. Author's reply to Grati and Benn. **Prenat Diagn.** 2017;37:1053-1054. **I.F. 5.02**
- 64) Spinella F, Fiorentino F, Biricik A, Bono S, Ruberti A, Cotroneo E, Baldi M, Cursio E, Minasi MG, Greco E. Extent of chromosomal mosaicism influences the clinical outcome of in vitro fertilization treatments. *Fertil Steril.* 2018;109:77-83 **I.F. 4.5**
- 65) Minasi MG, Fiorentino F, Ruberti A, Biricik A, Cursio E, Cotroneo E, Varricchio MT, Surdo M, Spinella F, Greco E. Genetic diseases and aneuploidies can be detected with a single blastocyst biopsy: a successful clinical approach. *Hum Reprod.* 2017;32:1770-1777. **I.F. 5.02**
- 66) Munné S, Spinella F, Grifo J, Zhang J, Beltran MP, Fragouli E, Fiorentino F Clinical outcomes after the transfer of blastocysts characterized as mosaic by high resolution Next Generation Sequencing- further insights. *Eur J Med Genet.* 2019 Aug 21:103741.
- 67) Allegretti M, Cottone G, Carboni F, Cotroneo E, Casini B, Giordani E, Amoreo CA, Buglioni S, Diodoro M, Pescarmona E, Zazza S, Federici O, Zeuli M, Conti L, Cigliana G, Fiorentino F, Valle M, Giacomini P, Spinella F. Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy. *J Exp Clin Cancer Res.* 2020 Apr 20;39(1):69
- 68) Wöhlke S, Schaper M, Oliveri S, Cutica I, Spinella F, Pravettoni G, Steinberger D, Schick Tanz S. German and Italian Users of Web-Accessed Genetic Data: Attitudes on Personal Utility and Personal Sharing Preferences. Results of a Comparative Survey (n=192). *Front Genet.* 2020 Mar 18;11:102. doi: 10.3389/fgene.2020.00102. eCollection 2020. PMID: 32265977
- 69) ESHRE PGT-SR/PGT-A Working Group, Coonen E, Rubio C, Christopikou D, Dimitriadou E, Gontar J, Goossens V, Maurer M, Spinella F, Vermeulen N, De Rycke M. ESHRE PGT Consortium good practice recommendations for the detection of structural and numerical chromosomal aberrations. *Hum Reprod Open.* 2020 May 29;2020(3).
- 70) La Marca A, Capuzzo M, Sacchi S, Imbrogno MG, Spinella F, Varricchio MT, Minasi MG, Greco P, Fiorentino F, Greco E. Comparison of euploidy rates of blastocysts in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation. *Hum Reprod.* 2020 Jun 1;35(6):1325-1331.
- 71) Dinami R, Porru M, Amoreo CA, Sperduti I, Mottolese M, Buglioni S, Marinelli D, Maugeri-Saccà M, Sacconi A, Blandino G, Leonetti C, Di Rocco G, Verdina A, Spinella F, Fiorentino F, Ciliberto G, Biroccio A, Zizza P. TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. *J Exp Clin Cancer Res.* 2020 Jun 15;39(1):111
- 72) La Marca A, Capuzzo M, Imbrogno MG, Donno V, Spedicato GA, Sacchi S, Minasi MG, Spinella F, Greco P, Fiorentino F, Greco E. The complex relationship between female age and embryo euploidy. *Minerva Ginecol.* 2020 Dec 11. doi: 10.23736/S0026-4784.20.04740-1.
- 73) Ganci F, Allegretti M, Manciooco V, Fiorentino F, Sanguineti G, Giacomini P, Pellini R, Spinella F, Blandino G. Two distinct TP53 mutations in HNSCC primary tumor: Only one circulates in the blood. *Oral Oncol.* 2020 Nov 21:105096.

- 74) Sacconi A, Donzelli S, Pulito C, Ferrero S, Spinella F, Morrone A, Rigoni M, Pimpinelli F, Ensoli F, Sanguineti G, Pellini R, Agrawal N, Izumchenko E, Ciliberto G, Gianni A, Muti P, Strano S, Blandino G. TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. *J Exp Clin Cancer Res.* 2020 Sep 23;39(1):200.
- 75) Donzelli S, Spinella F, di Domenico EG, Pontone M, Cavallo I, Orlandi G, Iannazzo S, Ricciuto GM, Isg Virology Covid Team, Pellini R, Muti P, Strano S, Ciliberto G, Ensoli F, Zapperi S, La Porta CAM, Blandino G, Morrone A, Pimpinelli F. Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects. *Comput Struct Biotechnol J.* 2022;20:733-744.
- 76) Ongaro G, Brivio E, Cincidda C, Oliveri S, Spinella F, Steinberger D, Cutica I, Gorini A, Pravettoni G. Genetic testing users in Italy and Germany: Health orientation, health-related habits, and psychological profile *Mol Genet Genomic Med.* 2022 Mar;10(3):e1851. doi: 10.1002/mgg3.1851.
- 77) Oliveri S, Marton G, Vergani L, Cutica I, Gorini A, Spinella F, Pravettoni G. Genetic Testing Consumers in Italy: A Preliminary Investigation of the Socio-Demographic Profile, Health-Related Habits, and Decision Purposes. *Front Public Health.* 2020 Oct 8;8:511. doi: 10.3389/fpubh.2020.00511
- 78) Oliveri S, Durosini I, Cutica I, Cincidda C, Spinella F, Baldi M, Gorini A, Pravettoni G. Health orientation and individual tendencies of a sample of Italian genetic testing consumers. *Mol Genet Genomic Med.* 2020 Aug;8(8):e1291. doi: 10.1002/mgg3.1291. Epub 2020 Jun 5. PMID: 32500972
- 79) Oliveri S, Cincidda C, Ongaro G, Cutica I, Gorini A, Spinella F, Fiorentino F, Baldi M, Pravettoni G. What people really change after genetic testing (GT) performed in private labs: results from an Italian study. *Eur J Hum Genet.* 2022 Jan;30(1):62-72. doi: 10.1038/s41431-021-00879-w.
- 80) Viotti M, Victor AR, Barnes FL, Zouves CG, Besser AG, Grifo JA, Cheng EH, Lee MS, Horcajadas JA, Corti L, Fiorentino F, Spinella F, Minasi MG, Greco E, Munné S. Using outcome data from one thousand mosaic embryo transfers to formulate an embryo ranking system for clinical use. *Fertil Steril.* 2021 Mar 5:S0015-0282(20)32716-3. doi: 10.1016/j.fertnstert.2020.11.041
- 81) Biricik A, Cotroneo E, Minasi MG, Greco PF, Bono S, Surdo M, Lecciso F, Sessa M, Fiorentino F, Spinella F, Greco E. Cross-Validation of Next-Generation Sequencing Technologies for Diagnosis of Chromosomal Mosaicism and Segmental Aneuploidies in Preimplantation Embryos Model. *Life (Basel).* 2021 Apr 12;11(4):340. doi: 10.3390/life11040340. PMID: 33921258; PMCID: PMC8069536
- 82) Viotti M, McCoy RC, Griffin DK, Spinella F, Greco E, Madjunkov M, Madjunkova S, Librach CL, Victor AR, Barnes FL, Zouves CG. Let the data do the talking: the need to consider mosaicism during embryo selection. *Fertil Steril.* 2021 Nov;116(5):1212-1219.
- 83) Somigliana E, Costantini MP, Filippi F, Terenziani M, Riccaboni A, Nicotra V, Rago R, Paffoni A, Mencaglia L, Magnolfi S, Zuccarello D, Rienzi L, Spinella F, Capalbo A, Scaravelli G, Testa S; MUTAGENS Special Interest Group on parenting and fertility. Fertility counseling in women with hereditary cancer syndromes. *Crit Rev Oncol Hematol.* 2022 Mar;171:103604
- 84) Greco E, Yakovlev P, Kornilov N, Vyatkina S, Bogdanova D, Ermakova M, Tarasova Y, Tikhonov A, Pendina A, Biricik A, Sessa MT, Listorti I, Ronsini C, Greco PF, Victor A, Barnes F, Zouves C, Spinella F, Viotti M. Two clinical case reports of embryonic mosaicism identified with PGT-A persisting during pregnancy as true fetal mosaicism. *Hum Reprod.* 2023 Feb 1;38(2):315-323.
- 85) Oliveri S, Ongaro G, Cutica I, Menicucci G, Belperio D, Spinella F, Pravettoni G. Decision-making process about prenatal genetic screening: how deeply do moms-to-be want to know from Non-Invasive Prenatal Testing? *BMC Pregnancy Childbirth.* 2023 Jan 18;23(1):38. doi: 10.1186/s12884-022-05272-z. PMID: 36653738
- 86) ESHRE PGT Consortium data collection XXI: PGT analyses in 2018. Spinella F, Bronet F, Carvalho F, Coonen E, De Rycke M, Rubio C, Goossens V, Van Montfoort A. *Hum Reprod Open.* 2023 Apr 19;2023(2):hoad010. doi: 10.1093/hropen/hoad010. eCollection 2023. PMID: 37091225
- 87) Greco E, Greco PF, Listorti I, Ronsini C, Cucinelli F, Biricik A, Viotti M, Meschino N, Spinella F. The mosaic embryo: what it means for the doctor and the patient. *Minerva Obstet Gynecol.* 2023 Jan 10. PMID: 37427860
- 88) Viotti M, Greco E, Grifo JA, Madjunkov M, Librach C, Cetinkaya M, Kahraman S, Yakovlev P, Kornilov N, Corti L, Biricik A, Cheng EH, Su CY, Lee MS, Bonifacio MD, Cooper AR, Griffin DK, Tran DY, Kaur P, Barnes FL, Zouves CG, Victor AR, Besser AG, Madjunkova S, Spinella F. Chromosomal, gestational, and neonatal outcomes of embryos classified as a mosaic by preimplantation genetic testing for aneuploidy. *Fertil Steril.* 2023 Nov;120(5):957-966.
- 89) Faieta M, Falcone R, Duca S, Corsetti E, Giannico R, Gigante L, Diano L, Calugi G, Spinella F, Pizzuti F. Test performance and clinical utility of expanded non-invasive prenatal test: Experience on 71,883

Rome 4, May 2024

Francesca Spinella